Welcome to the e-CCO Library!

OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Last Modified: Wednesday, 15 March 2017, 2:07 PM by ECCO Administrator
Tofacitinib, Crohn's Disease
Files: 1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Last Modified: Wednesday, 15 March 2017, 2:06 PM by ECCO Administrator
Tofacitinib, Ulcerative Colitis
Files: 1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Sands B.E.2, Danese S.3, D'Haens G.R.4, Vermeire S.5, Schreiber S.6, Feagan B.7, Reinisch W.8,9, Friedman G.10, Woodworth D.10, Zhang H.10, Lawendy N.10, Niezychowski W.10, Su C.10, Panés J.*11

Created: Wednesday, 20 February 2019, 10:36 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Moens1,2*, K. van Hoeve2,3, E. Humblet4, J.-F. Rahier5, P. Bossuyt6, S. Dewit7, D. Franchimont8, E. Macken9, J. Nijs10, A. Posen11, A. Van Hootegem12, W. Van Moerkercke13, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
Year: 2018
Source: ECCO'18 Vienna
Authors: Moens Annick
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, De Hertogh G.2, Chen G.3, French D.4, Huntzicker E.4, Van der Aa A.5, Van Kaem T.5, Harrison P.5, Tasset C.5, Galien R.6, Pan Y.4, Feagan B.7, Sandborn W.8

Created: Wednesday, 20 February 2019, 10:36 AM
OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3*, A. Armuzzi4, G.S. Friedman5, M. Moscariello5, N. Lawendy5, R.D. Pedersen5, G. Chan5, C.I. Nduaka5, D. Quirk5, L. Salese5, C. Su5

Created: Thursday, 21 February 2019, 9:14 AM
OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Reinisch W.
Last Modified: Wednesday, 15 March 2017, 2:04 PM by ECCO Administrator
Abrilumab
Files: 1
OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Hansen M.B.3, Feagan B.G.4, Loftus Jr. E.V.5, Rogler G.6, Vermeire S.7, Cruz M.L.2, Yang J.2, Sullivan B.A.2, Reinisch W.*8

Created: Wednesday, 20 February 2019, 10:36 AM
OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Calafat1,2*, M. Mañosa3,4, F. Cañete3, J. Panés4,5, V. García Sánchez4,6, M. Calvo7, F. Rodríguez-Moranta8, C. Taxonera9, P. Nos4,10, A. López Sanromán11, M.D. Martín Arranz12, M. Mínguez13, J.P. Gisbert4,14, S. García-López15, R. de Francisco16, F. Gomollón4,17, X. Calvet4,18, E. Garcia-Planella19, M. Rivero20, J. Martínez-Cadilla21, F. Argüelles22, L. Arias García23, M. Cimavilla24, Y. Zabana4,25, L. Márquez26, A. Gutiérrez4,27, G. Alcaín28, P. Martínez Montiel29, J. Lázaro30, D. Busquets31, M.F. García Sepulcre32, C. Verdejo33, F. Bermejo34, M. Mora35, D. Monfort36, P. Romero37, B. Velayos38, C. Rodríguez39, A. Rodríguez40, O. Merino41, A. Rodríguez-Pescador42, L. Bujanda4,43, Y. Ber44, M. Vela45, O. Roncero46, J.M. Huguet47, O. García-Bosch48, M. Barreiro-de-Acosta49, R.E. Madrigal50, L. Ramos51, M. Van Domselaar52, P. Almela53, J. Llaó54, A.J. Lucendo4,55, C. Muñoz Vilafranca56, À. Abad57, M. Charro58, J. Legido59, J. Riera1, S. Khorrami60, E. Sesé61, A.M. Trapero62, E. Domènech3,4

Created: Thursday, 21 February 2019, 9:14 AM
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
Year: 2018
Source: ECCO'18 Vienna
Authors: Walker Gareth
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

Created: Wednesday, 20 February 2019, 10:36 AM
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Reinisch W.
Last Modified: Wednesday, 15 March 2017, 2:03 PM by ECCO Administrator
Abrilumab
Files: 1
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Walker1,2*, J. Harrison3, M. Voskuil4, G. Heap1,2, N. Heerasing1,2, P. Hendy1,2, J. Koskela5,6, M. Daly5,6, H. Sokol7, D. McGovern8, R. Weersma4, C. Bewshea1, M. Weedon3, J. Goodhand1,2, N. Kennedy1,2, T. Ahmad1,2, IBD Pharmacogenetics Study Group

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Jong1*, S. van Tilburg1,2, L. Nissen2, W. Kievit1, I. Nagtegaal3, F. Hoentjen1, L. Derikx1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study
Year: 2018
Source: ECCO'18 Vienna
Authors: de Jong Michiel
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild- moderately active Ulcerative Colitis: A randomised controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Costello S.
Last Modified: Wednesday, 15 March 2017, 1:55 PM by ECCO Administrator
Microbiota, Faecal microbiota transplantation, environmental factors
Files: 1
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Costello S.*1,2,3, Waters O.4, Bryant R.2,3, Katsikeros R.3, Makanyanga J.4, Schoeman M.2,3, Mountifield R.5, Tee D.6, Howell S.2, Hughes P.2, Conlon M.7, Roberts-Thomson I.1,2, Andrews J.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life
Year: 2017
Source: ECCO'17 Barcelona
Authors: Torres J.
Last Modified: Wednesday, 15 March 2017, 1:56 PM by ECCO Administrator
Microbiota, IBD in pregnancy, environmental factors
Files: 1